Cirba Inc. (d/b/a Densify) v. VMware, Inc.

District Court, D. Delaware·Decided October 6, 2020·No. 1:19-cv-00742·Unknown

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE CIRBA INC, (d/b/a DENSIFY) : and CIRBA IP, INC., : Plaintiffs/Counter-Defendants, Vv. : C.A. No. 19-742-LPS VMWARE, INC., Defendant/Counter-Plaintiff. : Kenneth L. Dorsney, MORRIS JAMES, Wilmington, DE Courtland L. Reichman, Shawna Ballard, Jennifer P. Estremera, Michael G. Flanigan, Joachim B. Steinberg, Kate Falkenstien, and Ariel C. Green, REICHMAN JORGENSEN LLP, Redwood Shores, CA Peter J. Ayers, LAW OFFICE OF PETER J. AYERS, PLLC, Austin, TX Sarah O. Jorgensen, REICHMAN JORGENSEN LLP, Atlanta, GA Christine E. Lehman and Adam Adler, REICHMAN JORGENSEN LLP, Washington, DC Khue V. Hoang, Jaime Cardenas-Navia, Wesley L. White, and Rahul Sarkar, REICHMAN JORGENSEN LLP, New York, NY Attorneys for Plaintiffs/Counter-Defendants Anne Shea Gaza, Robert M. Vrana, and Samantha G. Wilson, YOUNG CONAWAY STARGATT & TAYLOR, LLP, Wilmington, DE Arturo J. Gonzalez, Michael A. Jacobs, and Richard S. J. Hung, MORRISON & FOERSTER LLP, San Francisco, CA Bita Rahebi, MORRISON & FOERSTER LLP, Los Angeles, CA Scott F. Llewellyn, MORRISON & FOERSTER LLP, Denver, CO Attorneys for Defendant/Counter-Plaintiff MEMORANDUM OPINION October 6, 2020 Wilmington, Delaware

(kVp \j—~ STARKSUSS. District Judge: Plaintiffs Cirba Inc. and Cirba IP, Inc. (collectively, “Plaintiffs” or “Densify”) originally filed suit against Defendant VMware, Inc. (“Defendant” or “VMware”) on April 25, 2019, alleging infringement of their U.S. Patent Nos. 8,209,687 (the “‘687 Patent”) and 9,654,367 (the “<367 Patent”). (D.I. 1) Densify’s patents relate to virtualization technology and management of virtual environments. VMware raised counterclaims for infringement of its U.S. Patent Nos. 8,875,266 (the “‘266 Patent”), 10,069,752 (the “‘752 Patent”), 8,336,049 (the “049 Patent”), and 9,521,151 (the “‘151 Patent”). (D.I. 150) On September 20, 2019, the Court granted Density’s motion to sever VMware’s counterclaims from the expedited trial schedule adopted for litigating Densify’s °687 and ’367 Patents. (D.1. 194) Following a nine-day jury trial on the two Densify patents in January 2020, and with post-trial motions relating to the jury’s verdict trial currently pending before the Court, the Court now turns to the issue of claim construction with respect to VMware’s asserted patents. The parties submitted their joint claim construction brief on July 9, 2020. (D.I. 788) The parties’ submissions include expert declarations. (D.I. 789 Exs. A-1, A-2, B-1) The Court held a claim construction hearing on August 7, 2020. (See D.I. 820 (“Tr.”)) LEGAL STANDARDS The ultimate question of the proper construction of a patent is a question of law. See Teva Pharm. USA, Inc. v. Sandoz, Inc., 135 S. Ct. 831, 837 (2015) (citing Markman v. Westview Instruments, Inc., 517 U.S. 370, 388-91 (1996)). “It is a bedrock principle of patent law that the claims of a patent define the invention to which the patentee is entitled the right to exclude.” Phillips v. AWH Corp., 415 F.3d 1303, 1312 (Fed. Cir. 2005) (internal citation and quotation marks omitted), “[T]here is no magic formula or catechism for conducting claim construction.”

Id. at 1324. Instead, the Court is free to attach the appropriate weight to appropriate sources “in light of the statutes and policies that inform patent law.” /d. “(T]he words of a claim are generally given their ordinary and customary meaning ... [which is] the meaning that the term would have to a person of ordinary skill in the art in question at the time of the invention, i.e., as of the effective filing date of the patent application.” Id. at 1312-13 (internal citations and quotation marks omitted). “[T]Jhe ordinary meaning of a claim term is its meaning to the ordinary artisan after reading the entire patent.” Jd. at 1321 (internal quotation marks omitted). The patent “specification is always highly relevant to the claim construction analysis. Usually, it is dispositive; it is the single best guide to the meaning of a disputed term.” Vitronics Corp. v. Conceptronic, Inc., 90 F.3d 1576, 1582 (Fed. Cir, 1996). While “the claims themselves provide substantial guidance as to the meaning of particular claim terms,” the context of the surrounding words of the claim also must be considered. Phillips, 415 F.3d at 1314. Furthermore, “[o]ther claims of the patent in question, both asserted and unasserted, can also be valuable sources of enlightenment . . . [b]ecause claim terms are normally used consistently throughout the patent.” Jd. (internal citation omitted). It is likewise true that “[d]ifferences among claims can also be a useful guide... For example, the presence of a dependent claim that adds a particular limitation gives rise toa presumption that the limitation in question is not present in the independent claim.” Jd. at 1314- 15 (internal citation omitted). This “presumption is especially strong when the limitation in dispute is the only meaningful difference between an independent and dependent claim, and one party is urging that the limitation in the dependent claim should be read into the independent claim.” SunRace Roots Enter. Co., Ltd. v. SRAM Corp., 336 F.3d 1298, 1303 (Fed. Cir. 2003).

It is also possible that “the specification may reveal a special definition given to a claim term by the patentee that differs from the meaning it would otherwise possess. In such cases, the inventor’s lexicography governs.” Phillips, 415 F.3d at 1316. It bears emphasis that “[e]ven when the specification describes only a single embodiment, the claims of the patent will not be read restrictively unless the patentee has demonstrated a clear intention to limit the claim scope using words or expressions of manifest exclusion or restriction.” Hill-Rom Servs., inc. v. Stryker Corp., 755 F.3d 1367, 1372 (Fed. Cir. 2014) (quoting Liebel-Flarsheim Co. v. Medrad, Inc., 358 F.3d 898, 906 (Fed. Cir. 2004)) (alteration in original) (internal quotation marks omitted). In addition to the specification, a court “should also consider the patent’s prosecution history, if it is in evidence.” Markman v. Westview Instruments, Inc. , 52 F.3d 967, 980 (Fed. Cir, 1995), aff'd, 517 U.S. 370 (1996). The prosecution history, which is “intrinsic evidence,” “consists of the complete record of the proceedings before the [Patent and Trademark Office] and includes the prior art cited during the examination of the patent.” Phillips, 415 F.3d at 1317. “(T{he prosecution history can often inform the meaning of the claim language by demonstrating how the inventor understood the invention and whether the inventor limited the invention in the

course of prosecution, making the claim scope narrower than it would otherwise be.” Jd. “In some cases...

Free access — add to your briefcase to read the full text and ask questions with AI

Cirba Inc. (d/b/a Densify) v. VMware, Inc., (D. Del. 2020).

Cirba Inc. (d/b/a Densify) v. VMware, Inc. (Cirba Inc. (d/b/a Densify) v. VMware, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

OSRAM GmbH v. International Trade Commission
505 F.3d 1351 (Federal Circuit, 2007)
Vitronics Corporation v. Conceptronic, Inc.
90 F.3d 1576 (Federal Circuit, 1996)
Nautilus, Inc. v. Biosig Instruments, Inc.
134 S. Ct. 2120 (Supreme Court, 2014)
Hill-Rom Services, Inc. v. Stryker Corporation
755 F.3d 1367 (Federal Circuit, 2014)
Kaneka Corp. v. Xiamen Kingdomway Group Co.
790 F.3d 1298 (Federal Circuit, 2015)
Richard Williamson v. Citrix Online, LLC
792 F.3d 1339 (Federal Circuit, 2015)
Zeroclick, LLC v. Apple Inc.
891 F.3d 1003 (Federal Circuit, 2018)
Teva Pharm. United States, Inc. v. Sandoz, Inc.
135 S. Ct. 831 (Supreme Court, 2015)